What is Arcus Biosciences Forward Dividend Yield %?
As of today (2024-06-05), the Forward Annual Dividend Yield of Arcus Biosciences is 0.00%.
As of today (2024-06-05), the Trailing Annual Dividend Yield of Arcus Biosciences is 0.00%.
RCUS's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.665 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Competitive Comparison of Arcus Biosciences's Forward Dividend Yield %
For the Biotechnology subindustry, Arcus Biosciences's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcus Biosciences's Forward Dividend Yield % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arcus Biosciences's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Arcus Biosciences's Forward Dividend Yield % falls into.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Arcus Biosciences Forward Dividend Yield % Related Terms
Thank you for viewing the detailed overview of Arcus Biosciences's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Arcus Biosciences (Arcus Biosciences) Business Description
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB680, and Zimberelimab. Arcus conducts clinical trials for different types of cancers such as Prostate, Lung, Colorectal, Pancreatic, and others. The company operates through the single segment being the business of developing and commercializing immunotherapies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RCUS has been successfully added to your